Koers Organogenesis Holdings Inc. Nasdaq
Aandelen
AHPAU
KYG0726L1095
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- USD | -.--% | +1,51% | +0,58% |
02/05 | Organogenesis behaalt primair eindpunt in fase 3 klinische studie van ReNu voor knieartrose | CI |
29/02 | Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024 |
Omzet 2024 * | 455 mln. 423 mln. | Omzet 2025 * | 490 mln. 456 mln. | Marktkapitalisatie | 323 mln. 301 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -2 mln. -1,86 mln. | Nettowinst (verlies) 2025 * | 8 mln. 7,44 mln. | EV/omzet 2024 * | 0,68 x |
Nettoliquiditeiten 2024 * | 15,31 mln. 14,24 mln. | Nettoliquiditeiten 2025 * | 14,68 mln. 13,65 mln. | EV/omzet 2025 * | 0,63 x |
K/w-verhouding 2024 * |
-183
x | K/w-verhouding 2025 * |
25,7
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 66,36% |
Recentste transcriptie over Organogenesis Holdings Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gary Gillheeney
CEO | Chief Executive Officer | 69 | 01-01-14 |
David Francisco
DFI | Director of Finance/CFO | 59 | 16-02-21 |
Patrick Bilbo
COO | Chief Operating Officer | 63 | 01-01-99 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Glenn Nussdorf
BRD | Director/Board Member | 70 | 01-01-03 |
Alan Ades
BRD | Director/Board Member | 86 | 01-01-03 |
Michael Driscoll
BRD | Director/Board Member | 63 | 15-02-22 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,74% | 46,81 mld. | |
-0,97% | 41,37 mld. | |
+47,07% | 41,29 mld. | |
-3,52% | 28,87 mld. | |
+11,12% | 26,06 mld. | |
-19,37% | 19,13 mld. | |
+31,18% | 12,39 mld. | |
-0,04% | 12,08 mld. | |
+0,39% | 11,96 mld. |
- Beurs
- Aandelen
- Koers ORGO
- Koers AHPAU